High-grade serous ovarian cancer (HGSOC) accounts for 70–80% of ovarian cancer deaths,
and overall survival has not changed significantly for several decades. In this Opinion article …

Financial Disclosure Prof. Menon has stock ownership and has received research funding
from Abcodia Ltd, a UCL spinout company with an interest in biomarkers and commercial …

Purpose Guidelines are limited for genetic testing for prostate cancer (PCA). The goal of this
conference was to develop an expert consensus-driven working framework for …

Background The cost-effectiveness of population-based panel testing for high-and moderate-
penetrance ovarian cancer (OC)/breast cancer (BC) gene mutations is unknown. We …

Background The presence of deleterious mutations in breast cancer 1 gene (BRCA1) or
breast cancer 2 gene (BRCA2) significantly increases the risk of developing some cancers …

Objectives Precision medicine (PM) aims to improve patient outcomes by stratifying or
individualizing diagnosis and treatment decisions. Previous reviews found inconclusive …

Ovarian cancer (OC) is the most lethal gynaecological malignancy. The search for a widely
affordable and accessible screening strategy to reduce mortality from OC is still ongoing …

More than 15 years have passed since the identification, through linkage, of 'first-
wave'susceptibility genes for common cancers (BRCA1, BRCA2, MLH1 and MSH2). These …

Recent advancements in next-generation sequencing have greatly expanded the use of
multi-gene panel testing for hereditary cancer risk. Although genetic testing helps guide …

Clinical criteria/Family history-based BRCA testing misses a large proportion of BRCA
carriers who can benefit from screening/prevention. We estimate the cost-effectiveness of …